Empowering People with Parkinson’s disease

Connecting People with Parkinson’s disease with their care team for a better quality of life at lower cost

Parkinson's disease is the fastest growing neurodegenerative disorder

Symptoms generally develop slowly over years. However, the progression of symptoms is different from one person to another due to the diversity of the disease.

1. Motor symptoms

Motor symptoms that affect movement include:
Tremor – a shaking of the hands, arms, or legs.
Rigidity – abnormal stiffness in a part of the body
Postural instability – impaired balance or difficulty standing or walking
Bradykinesia – gradual loss and slowing down of spontaneous movement

2. Non-motor symptoms

People with Parkinson’s are often more impacted by their non-motor symptoms than motor symptoms.
Examples of non-motor symptoms include fatigue, depression, apathy, difficulty swallowing or chewing, urinary problems, constipation, loss of smell, sleep problems, pain, and cognitive problems.

3. Quality of Life

Quality of Life (QoL) is a multi-dimensional construct, which consists of at least three broad domains: physical, mental and social.
QoL specifically focuses on the impact of an illness and/or treatment on patients’ perception of their status of health and on subjective well-being or satisfaction with life.

Globally, neurological disorders are the leading cause of disability.

Of these, Parkinson’s disease is the fastest growing and a global concern that is present in every region of the world. Although there is no cure, treatment options vary and include medication, physical activity, life-style changes and surgery.

An estimated 10 million people are diagnosed with Parkinson’s disease worldwide, and this does not consider the millions that are already living with Parkinson’s without being diagnosed. Recent forecasts estimate a doubling of patients in the next generation.

The annual cost of Parkinson’s disease in the United States alone is estimated at $52 billion for 1 million people living with the disease.

51 disease-modifying therapies and 48 symptomatic therapies are in clinical testing, the global pharma market for Parkinson’s is estimated to grow to $6 billion by 2022.

A 2013 study supported by the American Academy of Neurology (AAN) showed an 11% shortage in neurologists at that time and projected a 19% shortage by 2025.

1. Person with Parkinson’s and caregiver: better quality of life

Interdisciplinary monitoring, personalized care path

Healthier, more informed and more engaged people with Parkinson’s population

Helps people with Parkinson’s and caregivers feel more “in control” of their disease

Peer to peer interactions and community support to deal with quality of life issues

2. Clinicians and other health care providers: value-based care, telemedicine

Ability to drive patient compliance with prescribed plans and show proof of adherence

Access to real world data analytics to evaluate efficacy of plans and tailor dosages and treatment

Improved understanding of disease patterns, progression, treatments, path to recovery

Actionable interdisciplinary approach

3. Pharma and Clinical Research Organizations: efficacy and lower costs

Real World Evidence

Reduction in clinical trial costs

More scientific guidance based on data series of actual care pathways to optimize efficiency and effectiveness of drugs

Personalized medicine

4. Payers: lower costs

Access to real world data analytics to manage rising costs and improve outcomes

Monitoring system to improve adherence and apply rewards & incentives system

Better delivery and management of home care

Long term benefits ability to improve plans and policies for people with Parkinson’s

Our Partners

Our recent blogs